Adjuvant mitotane in adrenocortical carcinoma [9]

New England Journal of Medicine

Volumn 357, Issue 12, 2007, Pages 1256-1259

  Bertherat, Jérôme ^a   Coste, Joël ^b   Bertagna, Xavier ^c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Hôpital Cochin ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; MITOTANE;

ADJUVANT THERAPY; ADRENAL CORTEX CARCINOMA; CANCER PATIENT; CANCER STAGING; DISEASE FREE SURVIVAL; HUMAN; HYDROCORTISONE RELEASE; LETTER; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 34548853467     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc076267     Document Type: Letter

References (4)

1. Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007;356:2372-80.
2. Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990;322:1195-201.
3. Libé R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 2007;14:13-28.
4. Abiven G, Coste J, Groussin L, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 2006;91:2650-5.